BECTON, DICKINSON AND COMPANY (NYSE:BDX) Files An 8-K Submission of Matters to a Vote of Security Holders

BECTON, DICKINSON AND COMPANY (NYSE:BDX) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07.Submission of Matters to a Vote of Security Holders.

Story continues below

The 2018 Annual Meeting of Shareholders (“Annual Meeting”) of Becton, Dickinson and Company ("BD") was held on January23, 2018. The final results for each of the matters submitted to a vote of shareholders at the Annual Meeting are as follows:

Item No.1: All of the Board of Directors’ nominees for director were elected to serve for a term of one year and until their respective successors are elected and qualified, by the votes set forth in the table below.

Nominee

For

Against

Abstain

Broker Non-Votes

Catherine M. Burzik

181,838,712

396,011

193,110

22,051,642

R. Andrew Eckert

181,397,196

810,263

220,374

22,051,642

Vincent A. Forlenza

175,320,986

6,595,040

511,807

22,051,642

Claire M. Fraser

180,220,018

1,922,077

215,739

22,051,642

Christopher Jones

181,754,783

433,683

239,366

22,051,642

Marshall O. Larsen

177,509,354

4,689,592

228,887

22,051,642

Gary A. Mecklenburg

177,252,447

4,924,708

250,678

22,051,642

David F. Melcher

181,395,664

778,179

253,990

22,051,642

Willard J. Overlock, Jr.

175,740,608

6,413,574

273,651

22,051,642

Claire Pomeroy

181,235,694

960,909

231,230

22,051,642

Rebecca W. Rimel

181,323,801

925,961

178,071

22,051,642

Timothy M. Ring

180,662,688

1,507,137

258,008

22,051,642

Bertram L. Scott

177,363,501

4,809,359

254,973

22,051,642

ItemNo.2:The appointment of Ernst& Young as BD’s independent registered public accounting firm for fiscal year 2018 was ratified by the shareholders by the votes set forth in the table below.

For

Against

Abstain

199,034,587

5,231,650

213,239

ItemNo.3:The shareholders approved, on an advisory, non-binding basis, the compensation of BD’s named executive officers by the votes set forth in the table below.

For

Against

Abstain

Broker Non-Votes

173,791,716

8,100,379

535,738

22,051,642

Item No. 4: A shareholder proposal regarding an amendment to the Company's proxy access by-law was not approved by the votes set forth in the table below.

For

Against

Abstain

Broker Non-Votes

50,135,096

131,510,881

781,856

22,051,642


About BECTON, DICKINSON AND COMPANY (NYSE:BDX)

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings. BD Medical consists of various business units, including diabetes care, medication and procedural solutions, medication management solutions and pharmaceutical systems. The BD Life Sciences segment provides products for the safe collection and transport of diagnostics specimens, and instruments and reagent systems to detect a range of infectious diseases, healthcare-associated infections and cancers. The Company’s BD Life Sciences segment consists of various business units, including preanalytical systems, diagnostic systems and biosciences.

An ad to help with our costs